Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Advancing a Therapeutic Platform Based on tRNA Synthetases for Treatment of Fibrotic Lung Diseases

Friday, November 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: aTyr Pharma is advancing a therapeutic platform based on tRNA synthetases aimed at treating fibrotic lung diseases, including pulmonary sarcoidosis. The company is focused on its lead candidate, Efzofitimod, and has established research programs to support its development. This innovative approach may enhance treatment options for patients suffering from these conditions.
Price reaction · baseline $0.7703 (2025-11-06 close) · hit pre-market · 8 other ATYR headline(s) in the window, move may be shared
day 0 close
+6%
day 1
+2.6%
day 3 · peak
-6.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancement in therapeutic platform for fibrotic lung diseases.
  • Focus on tRNA synthetases shows innovative approach.
  • Potential for improving patient outcomes in pulmonary sarcoidosis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is aTyr Pharma's focus?

aTyr Pharma focuses on developing a therapeutic platform based on tRNA synthetases.

What is Efzofitimod?

Efzofitimod is a lead candidate aimed at treating fibrotic lung diseases.

Which diseases are targeted by aTyr's research?

The research targets fibrotic lung diseases, including pulmonary sarcoidosis.

What innovative approach is aTyr using?

aTyr is using tRNA synthetases to develop new treatment options.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare aTyr Pharma Efzofitimod fibrotic lung diseases pulmonary sarcoidosis tRNA synthetases
Last updated: Nov 7, 2025

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →